Adaptive Targeted Protein Degradation System

Publication ID: 24-11857519_0005_PTD

Published: October 28, 2025

Category:Future Evolutions & Paradigm Shifts

Legal Citation

pr1or.art Inc., “Adaptive Targeted Protein Degradation System,” Published Technical Disclosure No. 24-11857519_0005_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857519_0005_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,519.

Summary of the Inventive Concept

A novel system for targeted protein degradation that utilizes adaptive E3 ubiquitin ligase proteins, conditional bifunctional constructs, and real-time monitoring to enhance precision, efficacy, and personalized treatment.

Background and Problem Solved

The original patent described compounds and methods for targeted degradation of enhancer of zeste homolog 2 polypeptide. However, these methods were limited by their static nature, lack of adaptability to cellular signals, and potential off-target effects. The new inventive concept addresses these limitations by introducing adaptive E3 ubiquitin ligase proteins that self-modify their substrate specificity in response to cellular signals, thereby enhancing precision and efficacy.

Detailed Description of the Inventive Concept

The new system comprises novel E3 ubiquitin ligase proteins engineered to exhibit conditional, cell-type specific activity. These proteins are designed to self-modify their substrate specificity in response to cellular signals, allowing for real-time adaptation to changing cellular conditions. The system also includes bifunctional constructs that bind target proteins and E3 ubiquitin ligase proteins, enabling targeted protein degradation. Additionally, a biosensor is integrated to detect the ubiquitination status of target proteins, enabling real-time monitoring and personalized adjustment of protein degradation therapies.

Novelty and Inventive Step

The new claims introduce adaptive E3 ubiquitin ligase proteins, conditional bifunctional constructs, and real-time monitoring, which are novel and non-obvious compared to the original patent. The inventive step lies in the integration of these components to create a dynamic, adaptive system for targeted protein degradation.

Alternative Embodiments and Variations

Alternative embodiments include the use of different E3 ubiquitin ligase proteins, conditional constructs, and biosensors. Variations may include the application of the system to different diseases or conditions, such as cancer, neurodegenerative disorders, or infectious diseases.

Potential Commercial Applications and Market

The adaptive targeted protein degradation system has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the development of personalized therapies for cancer and other diseases. The system's ability to adapt to changing cellular conditions and provide real-time monitoring capabilities makes it an attractive solution for precision medicine applications.

CPC Classifications

Section	Class	Group
A	A61	A61K31/166
A	A61	A61K31/351
A	A61	A61K31/405
A	A61	A61K38/45
A	A61	A61K47/545
A	A61	A61K47/55
A	A61	A61K47/555
A	A61	A61P35/00
C	C07	C07D401/14
C	C07	C07D405/12
C	C07	C07D405/14
C	C07	C07D409/14
C	C07	C07D417/14
C	C07	C07D471/04
C	C12	C12N9/1007
C	C12	C12Y201/01043

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Pharmaceutical biotechnology, protein degradation therapeutics, with expertise in molecular biology, protein engineering, and targeted drug design

Person of Ordinary Skill (PHOSITA) Profile

A PhD-level researcher with advanced training in protein chemistry, molecular biology techniques, drug development, and experience with protein targeting and ubiquitin-mediated degradation strategies

Obviousness Rationale

A skilled practitioner would recognize that the PTD's adaptive E3 ubiquitin ligase system represents a predictable extension of existing protein degradation technologies, utilizing known molecular engineering principles to enhance substrate specificity and therapeutic precision. The disclosed variations combine well-understood protein modification techniques with established targeted degradation frameworks. The incremental improvements in cellular signal responsiveness and real-time monitoring represent logical technological progressions within the existing protein degradation paradigm.

Obvious Combinations & Variations

Source Patent Element

Targeted protein degradation using chemical linking moieties and ubiquitin-based mechanisms

PTD Variation

Adaptive E3 ubiquitin ligase proteins that self-modify substrate specificity

Obviousness Reasoning

Modifying protein binding domains to enhance specificity is a known technique in protein engineering, representing a predictable optimization of existing targeted degradation approaches

Source Patent Element

Bifunctional constructs for binding target proteins

PTD Variation

Conditional bifunctional constructs with cell-type specific activity

Obviousness Reasoning

Introducing cellular context-dependence is a standard design strategy in drug development, representing a finite set of predictable modifications to improve therapeutic precision

Source Patent Element

Chemical compounds for protein interaction and degradation

PTD Variation

Biosensor integration for real-time protein ubiquitination monitoring

Obviousness Reasoning

Adding monitoring capabilities to therapeutic systems is a well-established approach in personalized medicine, utilizing known sensor and molecular detection technologies

Source Patent Element

Pharmaceutical compositions for protein targeting

PTD Variation

Machine learning algorithms for predicting protein degradation therapy efficacy

Obviousness Reasoning

Applying computational methods to optimize drug design is a standard approach in modern pharmaceutical research, representing an obvious technological progression

Source Patent Element

Targeted protein degradation mechanisms

PTD Variation

Dynamic, adaptive protein degradation system with integrated feedback

Obviousness Reasoning

Creating closed-loop therapeutic systems with adaptive capabilities is a predictable innovation in drug design, utilizing standard molecular biology and systems engineering principles

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857519 and the disclosed technological variations, a person having ordinary skill in the art would find the claimed adaptive protein degradation system obvious and anticipated. The incremental modifications represent predictable extensions of existing targeted protein degradation technologies, combining known molecular engineering techniques with standard pharmaceutical design principles to achieve enhanced therapeutic specificity and monitoring capabilities.

Original Patent Information

Patent Number	US 11,857,519
Title	Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
Assignee(s)	Arvinas Operations, Inc.